v3.20.2
Condensed Consolidated Balance Sheets - USD ($)
Jul. 31, 2020
Oct. 31, 2019
Current assets:    
Cash and cash equivalents $ 5,928,007 $ 3,491,625
Short-term investments in certificates of deposit 3,140,000 2,350,000
Receivables 5,950 66,527
Prepaid expenses and other current assets 189,842 184,972
Total current assets 9,263,799 6,093,124
Property and equipment, net of accumulated depreciation of $95,015 200,569
Operating lease right-of-use asset 67,982
Other assets 30,000
Total assets 9,361,781 6,293,693
Current liabilities:    
Accounts payable 339,295 585,817
Accrued expenses 815,717 895,498
Operating lease liability 58,195
Total current liabilities 1,213,207 1,481,315
Operating lease liability, non-current 10,567
Total liabilities 1,223,774 1,481,315
Commitments and contingencies (Note 9)
Shareholders' equity:    
Preferred stock, value
Common stock, par value $.01 per share; 48,000,000 shares authorized; 23,653,754 and 20,331,754 shares issued and outstanding, respectively 236,537 203,317
Additional paid-in capital 197,993,060 186,849,299
Accumulated deficit (189,611,583) (181,817,263)
Total shareholders' equity 8,618,014 5,235,353
Noncontrolling interest (Note 1) (480,007) (422,975)
Total equity 8,138,007 4,812,378
Total liabilities and equity 9,361,781 6,293,693
Series A Convertible Preferred Stock [Member]    
Shareholders' equity:    
Preferred stock, value

Source

v3.20.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Jul. 31, 2020
Jul. 31, 2019
Jul. 31, 2020
Jul. 31, 2019
Income Statement [Abstract]        
Revenue $ 250,000
Operating costs and expenses:        
Patent assertion expenses 166,250
Amortization of patents 41,875 418,750
Research and development expenses (including non-cash share-based compensation expenses of $394,842, $338,449, $1,250,497 and $2,567,294, respectively) 1,254,131 1,085,574 3,973,509 4,602,239
General and administrative expenses (including non-cash share-based compensation expenses of $646,957, $492,449, $1,922,722 and $2,335,218, respectively) 1,181,838 1,056,963 3,762,466 4,405,385
Impairment in carrying amount of patent asset 418,750
Total operating costs and expenses 2,435,969 2,184,412 7,735,975 10,011,374
Loss from operations (2,435,969) (2,184,412) (7,735,975) (9,761,374)
Other Expense (148,084) (148,084)
Interest income 7,266 18,364 32,707 53,783
Net loss (2,576,787) (2,166,048) (7,851,352) (9,707,591)
Less: Net loss attributable to noncontrolling interest (15,103) (26,020) (57,032) (148,030)
Net loss attributable to common shareholders $ (2,561,684) $ (2,140,028) $ (7,794,320) $ (9,559,561)
Net loss per common share attributable to common shareholders: Basic and diluted $ (0.11) $ (0.11) $ (0.36) $ (0.49)
Weighted average common shares outstanding: Basic and diluted 23,165,066 20,100,915 21,678,608 19,638,833

Source

v3.20.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended
Jul. 31, 2020
Jul. 31, 2019
Reconciliation of net loss to net cash used in operating activities:    
Net loss $ (7,851,352) $ (9,707,591)
Stock option compensation to employees and directors 3,016,305 2,808,910
Stock options and warrants issued to consultants 156,914 139,161
Restricted stock award compensation to employee pursuant to stock incentive plan 1,954,441
Depreciation of property and equipment 38,276 32,990
Loss on disposal of property and equipment 148,084
Amortization of operating lease right-of-use asset 38,317
Amortization of patents 418,750
Impairment in carrying amount of patent assets 418,750
Change in operating assets and liabilities:    
Receivables 60,577 305,919
Prepaid expenses and other current assets (4,870) 45,847
Accounts payable (246,522) (14,234)
Accrued expenses (79,781) 192,672
Operating lease liability (37,537)
Net cash used in operating activities (4,761,589) (3,404,385)
Cash flows from investing activities:    
Disbursements to acquire short-term investments in certificates of deposit (5,510,000) (2,350,000)
Proceeds from maturities of short-term investments in certificates of deposit 4,720,000 2,250,000
Purchase of property and equipment (15,791) (175,457)
Net cash used in investing activities (805,791) (275,457)
Cash flows from financing activities:    
Net proceeds from sale of common stock in at-the-market offering 7,866,040 4,899,745
Proceeds from sale of common stock pursuant to employee stock purchase plan 15,452 18,560
Proceeds from exercise of stock options 122,270 102,500
Net cash provided by financing activities 8,003,762 5,020,805
Net increase in cash and cash equivalents 2,436,382 1,340,963
Cash and cash equivalents at beginning of period 3,491,625 3,055,890
Cash and cash equivalents at end of period 5,928,007 4,396,853
Supplemental disclosure of non-cash investing and financing activities:    
Operating lease right-of-use asset (106,221)
Operating lease liability $ 106,299

Source